Tag: pharmaceuticals
-
Delivery Technique Devised to Cross Blood-Brain Barrier
21 October 2015. Medical researchers developed a technique that allows drugs for treating neurological disorders to penetrate the blood-brain barrier, a difficult obstacle up to now. The team led by ear, nose, and throat, or ENT, specialist Benjamin Bleier at Massachusetts Eye and Ear Hospital and Harvard Medical School described its methods with lab mice…
-
Immunotherapy Start-Up Gains $102M in Venture Funds
20 October 2015. A new enterprise founded by researchers in the U.S. and Europe that aims to provide personalized cancer therapies harnessing the immune system raised $102 million in its first round of venture financing. The company Gritstone Oncology — in San Francisco and Cambridge, Massachusetts — says it plans to focus initially on developing…
-
Evotec, Foundation Partner on Rare Juvenile Disease
20 October 2015. The drug discovery company Evotec AG and Beyond Batten Disease Foundation are collaborating on discovery of new drugs to treat juvenile Batten disease, a rare inherited neurodegenerative disorder. Financial details of the partnership were not revealed. Batten disease is a rare genetic condition of the nervous system that in most cases begins…
-
Novartis Licensing Depression Therapy Technology
19 October 2015. Luc Therapeutics, a biotechnology company designing treatments for psychiatric and neurological disorders, is licensing part of its technology to the pharmaceutical company Novartis to develop treatments for depression. Dollar amounts paid under the agreement to Luc Therapeutics, in Cambridge, Massachusetts, were not disclosed. Depression is a widespread condition, which when it becomes…
-
Cancer Institute Spins-Off Company, Gains Licensing Deal
14 October 2015. Ontario Institute for Cancer Research is spinning off a new enterprise to discover therapies for blood-related cancers, and will partner with Janssen Biotech Inc. to take those therapies to market. The licensing deal between Novera Therapeutics Inc., the OICR spin-off company in Toronto, and Janssen Biotech, a division of Johnson & Johnson,…
-
Institute, GlaxoSmithKline ID Tuberculosis Candidates
13 October 2015. A biomedical research institute partnered with a lab backed by pharmaceutical company GlaxoSmithKline to identify candidates for drugs that act on bacteria causing tuberculosis. The team from Center for Infectious Disease Research in Seattle and Tres Cantos Open Lab Foundation, a lab in Spain sponsored by GlaxoSmithKline, published its findings in a…
-
Chip Device in Development to Simulate Human Gut
9 October 2015. A team of medical researchers and engineers in North Carolina is developing a miniaturized device derived from human stem cells to better simulate the workings of a human gut. The five-year project is funded by $5.3 million grant from National Institute of Diabetes and Digestive and Kidney Diseases, part of National Institutes…
-
Eli Lilly Expanding NYC Labs for Cancer Therapies
9 October 2015. The pharmaceutical company Eli Lilly and Company is expanding its research labs in New York City to boost discoveries of cancer therapies that harness the immune system. Lilly expects to hire 50 more research and support staff as part of the expansion. The company’s new facility will inhabit 30,000 square feet in…
-
MD Anderson, Biotech Form Antibody Discovery Company
7 October 2015. MD Anderson Cancer Center in Houston is partnering with the biotechnology company Theraclone Sciences to form a new enterprise devoted to discovering antibodies for cancer therapies harnessing the immune system. The company named OncoResponse, also based in Houston, attracted $9.5 million in its first venture funding round. OncoResponse plans to adapt Theraclone’s…
-
Influenza A Therapy Shown Working in Trial
5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million from the U.S. Department of Health and Human Services to further…